|
FDA Lays Out First Set of User Fee Rates for Biosimilars
Biosimilars makers must dole out nearly $2 million in fees for applications requiring clinical data in fiscal 2013, while companies submitting applications without such data, or supplemental apps, will need to fork over half that amount.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives